Abstract
Liver metastases from colorectal cancer (CRC) have a poor prognosis. Despite recent advances in the management of advanced disease with chemotherapy, liver resection remains the only hope for cure for patients with colorectal liver metastases. Approximately 15% of patients with stage IV CRC referred to specialist centers have metastatic liver disease deemed to be resectable at presentation. Over the last five years, combination chemotherapeutic regimens, namely 5-fluorouracil/folinic acid with irinotecan or oxaliplatin and, more recently, integrating targeted monoclonal antibodies, have been shown to downsize the tumour burden to an extent that sometimes allows initially unresectable metastases to be excised. Five-year survival rates following liver resection range between 25% and 55% compared with 0% and 5% for non-operated patients. Beyond liver resection, the rationale for “pseudo-adjuvant” chemotherapy lacks scientific evidence, despite some promising data. However, perioperative chemotherapy for resectable lesions is gaining ground in current practice. In this article we review the state of the art treatment for CRC liver metastases and, considering the results of recent trials, try to determine the appropriate role of chemotherapy.
Keywords: Colorectal liver metastases treatment, review
Reviews on Recent Clinical Trials
Title: Treatment of Colorectal Liver Metastases: A Review
Volume: 4 Issue: 1
Author(s): M. Van den Eynde and A. Hendlisz
Affiliation:
Keywords: Colorectal liver metastases treatment, review
Abstract: Liver metastases from colorectal cancer (CRC) have a poor prognosis. Despite recent advances in the management of advanced disease with chemotherapy, liver resection remains the only hope for cure for patients with colorectal liver metastases. Approximately 15% of patients with stage IV CRC referred to specialist centers have metastatic liver disease deemed to be resectable at presentation. Over the last five years, combination chemotherapeutic regimens, namely 5-fluorouracil/folinic acid with irinotecan or oxaliplatin and, more recently, integrating targeted monoclonal antibodies, have been shown to downsize the tumour burden to an extent that sometimes allows initially unresectable metastases to be excised. Five-year survival rates following liver resection range between 25% and 55% compared with 0% and 5% for non-operated patients. Beyond liver resection, the rationale for “pseudo-adjuvant” chemotherapy lacks scientific evidence, despite some promising data. However, perioperative chemotherapy for resectable lesions is gaining ground in current practice. In this article we review the state of the art treatment for CRC liver metastases and, considering the results of recent trials, try to determine the appropriate role of chemotherapy.
Export Options
About this article
Cite this article as:
Eynde Van den M. and Hendlisz A., Treatment of Colorectal Liver Metastases: A Review, Reviews on Recent Clinical Trials 2009; 4 (1) . https://dx.doi.org/10.2174/157488709787047558
DOI https://dx.doi.org/10.2174/157488709787047558 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry Activation of LINE-1 Retrotransposon Increases the Risk of Epithelial-Mesenchymal Transition and Metastasis in Epithelial Cancer
Current Molecular Medicine FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Impact of Epigenetic Dietary Components on Cancer through Histone Modifications
Current Medicinal Chemistry Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies
Current Drug Targets Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Fatty Acid Amide Hydrolase: A Potential Target for Next Generation Therapeutics
Current Pharmaceutical Design Nano-Phytosome: A Developing Platform for Herbal Anti-Cancer Agents in Cancer Therapy
Current Drug Targets The Current View on the Helicase Activity of RNA Helicase A and Its Role in Gene Expression
Current Protein & Peptide Science Expression of Heme Oxygenase-1 in Response to Proteasomal Inhibition
Protein & Peptide Letters High Throughput Screening of Genetic Polymorphisms by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry
Combinatorial Chemistry & High Throughput Screening Involvement of Nucleotide Excision and Mismatch Repair Mechanisms in Double Strand Break Repair
Current Genomics The Role of Autophagic Cell Death and Apoptosis in Irinotecan-treated p53 Null Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Tumor Stroma as a Target in Cancer
Current Cancer Drug Targets Potential Molecular Targets of Ampelopsin in Prevention and Treatment of Cancers
Anti-Cancer Agents in Medicinal Chemistry Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism Role of the Non-Receptor Tyrosine Kinase Fes in Cancer
Current Medicinal Chemistry Mechanism of Drug Sensitivity and Resistance in Melanoma
Current Cancer Drug Targets